Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13344 | 0.81 | HTR6 (0.38) | TLR9TLR8TLR7SMN1; SMN2 | |
| SCHEMBL18207814 | 0.79 | SMN1; SMN2 (0.35) | TLR9TLR8TLR7SMN1; SMN2 | |
| SCHEMBL7450157 | 0.78 | — | — | |
| SCHEMBL3581397 | 0.78 | SMN1; SMN2 (0.36) | TLR9TLR8TLR7PIK3R1PIK3CA | |
| SCHEMBL18664079 | 0.76 | TLR9 (0.34) | TLR9TLR8TLR7SMN1; SMN2OPRM1 | |
| SCHEMBL13405622 | 0.76 | SMN1; SMN2 (0.35) | TLR9TLR8TLR7SMN1; SMN2OPRM1 | |
| SCHEMBL18664071 | 0.76 | TLR9 (0.34) | TLR9TLR8TLR7SMN1; SMN2OPRM1 | |
| SCHEMBL13931066 | 0.76 | HTR6 (0.47) | TLR9TLR8TLR7SMN1; SMN2 | |
| SCHEMBL18664072 | 0.76 | TLR9 (0.34) | TLR9TLR8TLR7SMN1; SMN2OPRM1 | |
| SCHEMBL193442 | 0.75 | PHGDH (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819667-B1 | SULFONAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY INC (US) | 2012-10-17 | — | — | EP | disclosed |
| US-8163735-B2 | Sulfonamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090233909-A1 | Sulfonamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| EP-1866276-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CELERA GENOMICS (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1819667-A1 | SULFONAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006102423-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CELERA GENOMICS (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006060810-A1 | SULFONAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233909-A1 | Sulfonamide compounds as cysteine protease inhibitors | CTSF, CTSS, CSTB | TLR9 4717/4885TLR8 4699/4885TLR7 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.